approved glp-1 agonists New Guidelines for Type 2 Diabetes in 2025 CAS 2381089-83-2 Size:180 Count The growing availability of

approved glp-1 agonists New Guidelines for Type 2 Diabetes in 2025 CAS 2381089-83-2 Size:180 Count The growing availability of

The growing availability of compounded GLP-1 weight-loss drugs has prompted warnings from doctors and the U.S. Food and Drug Administration.

This data shows that users in clinical trials lost more weight than real-world users when taking GLP-1 medications

CAS 2381089-83-2

Size:180 Count

Patients with Upper Gastrointestinal Disease A recently reported study focusing on patients with upper gastrointestinal disease, either chronic gastritis, gastroesophageal reflux disease, or both, undergoing GLP-1 RA treatment showed that this medication was well tolerated, with no need for dose adjustment